# CNBX Pharmaceuticals Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/CNBX Pharmaceuticals Inc.).

## Overview

CNBX Pharmaceuticals Inc. is a Bethesda, Maryland-based clinical-stage biopharmaceutical company focused on cannabinoid-based therapies for cancer. The company’s current lead programs include Cannabics SR, an oral capsule being developed for advanced cancer and cancer anorexia cachexia syndrome, and RCC-33, a first-in-class candidate for colorectal cancer. CNBX has shifted through several prior business models, including mining and oil and gas, and has operated as a biotech company since 2014. Its research and development work has been conducted through licensed facilities in Israel, while commercialization is intended to rely on licensing and third-party partners rather than an internal sales force. The company is still pre-commercial and has not generated meaningful product revenue from its drug pipeline.

## Products & services

• Cannabics SR oral capsule for advanced cancer and CACS
• RCC-33 colorectal cancer drug candidate
• Cannabinoid-based oncology R&D platform
• Licensing of intellectual property to partners
• Outsourced CMC and GMP development support

- **Lead drug candidates** (0%) — Clinical and pre-clinical oncology assets such as Cannabics SR and RCC-33.
- **Research and development platform** (0%) — Discovery work on cannabinoid-based therapies and administration routes for cancer.
- **Licensing and partnering** (0%) — Potential commercialization model based on out-licensing and strategic collaborations.
- **Contract laboratory services** (100%) — Historical laboratory services revenue generated outside the core drug pipeline.

- Cannabics SR oral capsule for advanced cancer and CACS
- RCC-33 colorectal cancer drug candidate
- Cannabinoid-based oncology R&D platform
- Licensing of intellectual property to partners
- Outsourced CMC and GMP development support

## Customers

CNBX’s direct customers are not yet established in the way they would be for a commercial pharmaceutical company, because the business is still in development and has no internal sales infrastructure. In the near term, the relevant counterparties are likely to be clinical trial partners, research collaborators, contract manufacturers, and potential licensing partners that can help advance RCC-33 and other candidates through development. If products are approved, the end customers would be physicians, hospitals, oncology clinics, and patients in cancer indications such as colorectal cancer and advanced cancer/CACS. The company also depends on investors and strategic partners to fund development, since it has limited cash flow and no meaningful operating revenue from product sales. Historical revenue from laboratory services indicates that non-core service customers have also contributed modestly in the past.

- **Clinical development partners** (primary) — Research institutions, CROs, and trial collaborators that support preclinical and Phase I/II development of RCC-33 and other oncology candidates.
- **Potential licensing partners** (primary) — Pharmaceutical or biotech companies that may license CNBX intellectual property to commercialize products in the U.S. or abroad.
- **Healthcare providers and patients** (primary) — Oncologists, hospitals, and cancer patients who would be the eventual users of approved cannabinoid-based cancer therapies.
- **Manufacturing and API partners** (secondary) — GMP suppliers and outsourced CMC providers that supply active ingredients and technical packages for regulatory filings.
- **Laboratory services customers** (emerging) — Customers for non-core lab services that produced limited historical revenue while the company was still early stage.

- Clinical trial partners that help test RCC-33 and related oncology assets
- Potential licensees that may commercialize CNBX programs outside the company
- Contract manufacturers and API suppliers supporting GMP/CMC work
- Oncology physicians and hospitals that would prescribe approved therapies
- Cancer patients, especially colorectal cancer and advanced cancer/CACS populations
- Laboratory services customers that generated historical non-pipeline revenue

## Geography

CNBX is headquartered in Bethesda, Maryland in the United States, and its corporate decision-making and financing activities are centered there. The company states that its R&D has been conducted in a government-licensed laboratory facility in Israel, making Israel an important operational base for research and regulatory permissions. It also notes that commercialization outside the United States may rely on strategic partners, which would broaden geographic exposure if products progress to market. Because CNBX is still pre-commercial, geography matters more for where research is performed and where regulatory approvals are needed than for current sales concentration. No authoritative country-level revenue split was disclosed in the provided excerpts.

- Headquartered in Bethesda, Maryland, United States
- Research and development conducted in licensed laboratory facilities in Israel
- U.S. FDA pathway is central for future clinical and commercial approval
- Potential non-U.S. commercialization may depend on strategic partners
- Current revenue is not geographically diversified because the company is pre-commercial

## Strategy

CNBX’s strategy is to advance its oncology pipeline through preclinical work and into first-in-human Phase I/II studies, with RCC-33 as the main near-term focus. The company intends to use outsourced GMP manufacturing and third-party CMC support rather than building internal manufacturing infrastructure, which reduces fixed cost but increases dependence on vendors. Management also expects to commercialize primarily through licensing and strategic partnerships, especially outside the United States, because it does not have a sales or distribution organization. A further strategic theme is opportunistically adding programs in high-unmet-need oncology areas through acquisition, collaboration, or internal development. The company’s ability to execute this strategy depends heavily on financing, regulatory progress, and partner availability.

- **Move RCC-33 into clinical testing** (short-term) — Clinical entry is the key value-creation step for a pre-clinical oncology company and is required to validate the asset.
- **Secure development financing** (short-term) — The company has limited cash flow and needs external capital to fund trials, regulatory work, and operating expenses.
- **Build a partnering and licensing model** (medium-term) — CNBX lacks sales, marketing, and distribution infrastructure, so commercialization depends on third parties.

- Advance RCC-33 into Phase I/II clinical trials
- Use outsourced GMP and CMC support instead of internal manufacturing
- Pursue a licensing-based commercialization model
- Seek strategic partners for non-U.S. markets
- Add oncology programs through acquisition or collaboration
- Preserve capital by keeping the operating footprint lean

## Risks

The most immediate risk is going concern risk, as auditors have expressed substantial doubt about the company’s ability to continue operating without additional financing. CNBX has not generated significant revenue from its core biotechnology business, so its ability to fund development depends on capital markets and investor appetite for early-stage biotech. Regulatory risk is also high because the company must obtain FDA clearance for clinical trials and eventual product approval, while its research activities have also depended on Israeli licensing and approved laboratory settings. Commercial risk is elevated because the company has no sales, marketing, or distribution infrastructure and may need to rely on partners whose incentives and execution it cannot fully control. More broadly, oncology drug development faces scientific failure risk, reimbursement risk, competition from better financed peers, and product liability exposure if a therapy reaches patients.

- **Going concern and financing shortfall** [critical] — Auditors disclosed substantial doubt about the company’s ability to continue as a going concern, and the business requires external capital to fund operations.
- **Clinical development failure** [high] — RCC-33 is still pre-clinical/early clinical, so efficacy, safety, and trial execution remain unproven.
- **Regulatory approval risk** [high] — The company must satisfy FDA requirements for IND filing, clinical trials, and eventual commercialization.
- **Commercial partner dependence** [high] — CNBX has no internal sales, marketing, or distribution capability and intends to rely on third parties or licensees.
- **Israel operating and licensing exposure** [medium] — Research has been conducted in Israel under local licensing, so permissions and cross-border operations are important to execution.

- Going concern risk due to limited cash and dependence on new financing
- Clinical and regulatory failure risk for RCC-33 and other oncology assets
- Commercialization risk because CNBX lacks sales and distribution infrastructure
- Partner dependence risk for licensing, manufacturing, and market access
- Scientific development risk common to early-stage oncology programs
- Competition for capital from better financed biotech peers
- Product liability and post-approval safety risk if a therapy reaches market

## Accounting

The most important accounting issue for CNBX is the going concern basis, because management’s ability to continue operations depends on future financing and/or profitable operations. As a pre-commercial biotech company, reported results are highly sensitive to the timing and level of R&D and general and administrative spending, which can change materially quarter to quarter as programs are paused or resumed. Revenue recognition is also limited and non-core, with the company reporting no revenue in fiscal 2025 versus modest laboratory-services revenue in fiscal 2024, so investors should not extrapolate historical revenue into the pipeline business. Share-based compensation, convertible loans, and interest on converted loans can materially affect reported expenses and financial income/loss even when cash usage is modest. Because the company is early stage and asset-light, there is also limited balance-sheet support from recurring revenue, making estimates around liabilities, financing instruments, and potential dilution especially important.

- **Going concern assessment** — High sensitivity to financing assumptions
- **Revenue recognition for non-core laboratory services** — Limited and non-recurring revenue base
- **Share-based compensation** — Non-cash expense affects operating loss
- **Convertible loans and interest** — Can create volatility in non-operating results

- Going concern basis is central because the company may need additional financing to continue
- Revenue is minimal and historically came from laboratory services, not product sales
- Quarterly operating expenses can swing with R&D activity and staffing levels
- Share-based compensation can materially affect G&A expense
- Convertible loans and related interest can distort financial income/loss
- Early-stage biotech estimates and liabilities are sensitive to management judgment

---

*Last updated: 2026-08-11T04:46:26.539625+00:00*